NFX vs. ROQ, BSFA, EVG, IXI, MTFB, FAB, VAL, DEST, RENE, and SALV
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), Evgen Pharma (EVG), IXICO (IXI), Motif Bio (MTFB), Fusion Antibodies (FAB), ValiRx (VAL), Destiny Pharma (DEST), ReNeuron Group (RENE), and SalvaRx Group (SALV). These companies are all part of the "biotechnology" industry.
Nuformix (LON:NFX) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.
In the previous week, Roquefort Therapeutics had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Nuformix. Nuformix's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.
Nuformix received 68 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Nuformix's return on equity of -27.25% beat Roquefort Therapeutics' return on equity.
Nuformix has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.
Nuformix has higher revenue and earnings than Roquefort Therapeutics.
0.1% of Nuformix shares are owned by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are owned by institutional investors. 15.0% of Nuformix shares are owned by insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Nuformix beats Roquefort Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
